MedTrace Logo

Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

NCT03925727 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 623

Last updated 2023-04-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions compared with placebo ophthalmic solution in treating the signs and symptoms of dry eye.

Conditions

  • Keratoconjunctivitis Sicca
  • Dry Eye

Interventions

DRUG

Tavilermide ophthalmic solution

BID topical dosing

OTHER

Placebo

BID topical dosing

Sponsors & Collaborators

  • Mimetogen Pharmaceuticals USA, Inc.

    lead INDUSTRY

Principal Investigators

  • Karen Meerovitch, PhD · Mimetogen Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-28
Primary Completion
2020-06-11
Completion
2020-06-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03925727 on ClinicalTrials.gov